ArticleEuropean journal of cancer (Oxford, England : 1990)2025
Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis.
Article in European journal of cancer (Oxford, England : 1990), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging and characterization of pulmonary nodules in children with solid tumors: what makes a pulmonary nodule a metastasis?Pediatric radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeAlthough the prognosis for patients with metastatic rhabdomyosarcoma (RMS) is generally unfavorable, outcomes can vary significantly depending on the extent of metastatic spread. This study focuses on the specific subgroup of patients presenting with a single metastatic site, aiming to better define their clinical characteristics and outcomes.
methodsPatients with a diagnosis of RMS and single-site metastatic involvement, collected in the INSTRuCT database were included. Clinical and pathological data were analyzed, with event-free survival (EFS) and overall survival (OS) as primary outcomes.
resultsOf 1095 metastatic patients, 497 (45.4 %) had single-site metastasis: 187 in lung, 83 in distant lymph nodes, 72 in bone marrow, 53 in bone, and 102 in other sites. Most patients with lung-only metastasis had embryonal histology. Compared to patients with multiple metastatic sites (5-year EFS: 16.4 %, 95 %CI 13.5-19.6; OS: 19.8 %, 95 % CI 16.6-23.2), those with single-site metastasis had better outcomes, showing 5-year EFS of 39.7 % (95 % CI 33.7-42.4) and OS of 47.0 %, (95 % CI 42.4-51.5) with significant site differences: 5-year OS was 53.3 % (95 % CI 45.8-60.3) for lung, 49.2 % (95 %CI 37.2-60.2) for lymph nodes, and 53.0 % (95 %CI 42.6-62.4) for other sites, but only 33.5 % (95 %CI 20.2-47.3) for bone and 28.7 % (95 %CI 18.5-39.7) for bone marrow (p = 0.0006). The presence of a fusion transcript negatively impacted prognosis for distant nodes (5-year EFS: 35.7 % vs. 63.6 %), lungs (10.0 % vs. 49.5 %), and other sites (13.6 % vs. 65.5 %).
conclusionWithin the patients with metastatic RMS, those with distant tumor isolated in lung, lymph node, or 'other' sites are associated with lower risk of events, while bone and bone marrow metastasis indicate poorest prognosis. The fusion transcript plays an important role in specific subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.